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The terminal RNA regions of the genomic and antigenomic RNAs of the paramyxoviruses and rhabdoviruses are known
to contain sequences essential for RNA replication and transcription. The 39- and 59-termini of human parainfluenza virus
type 3 (HPIV3) genomic RNA, termed leader and trailer sequences, respectively, are capable of forming stable stem-loop
structures. Additionally, the 17 terminal bases of the leader and trailer are complementary and therefore also capable of
forming a helical structure. We investigated the roles of the stem-loop structure and terminal complementarity in HPIV3 RNA
replication and transcription in vivo using a minigenome containing all RNA elements necessary for these processes. By
mutational analysis, we show that the RNA secondary structure features present at the termini of HPIV3 have no discernible
role in replication or transcription. Rather, the primary sequence of these regions is what is critical in promoting replication.
Interestingly, a mutation at leader base 24 was found to revert a mutation at leader position 5 but probably not via RNA
secondary structure restoration. © 2000 Academic PressINTRODUCTION
Human parainfluenza virus type 3 (HPIV3), a member
of the respirovirus genus of the family Paramyxoviridae,
is an enveloped, nonsegmented, negative-stranded RNA
virus of 15,462 nucleotides (Collins et al., 1996a). HPIV3
is important as a common cause of severe lower respi-
ratory tract infections in infants and young children for
which no effective antiviral therapy or vaccine is cur-
rently available (Collins et al., 1996a; Glezen et al., 1984;
Parrott et al., 1959; Welliver et al., 1986; Dolin, 1994).
HPIV3 replication begins with attachment to cell surface
receptors and release of the viral ribonucleoprotein
(RNP) into the cytoplasm. The RNP is the central unit for
viral transcription and replication and contains viral RNA
tightly encapsidated by the nucleocapsid protein (N), a
complex termed the N-RNA. The viral phosphoprotein
(P), large polymerase protein (L), and specific host pro-
teins associate with the N-RNA, which serves as the
template for RNA synthesis, to form the RNP (Collins et
al., 1996a). Transcription is the first RNA synthetic event
after entry of the RNP into the cytoplasm. Transcription is
believed to initiate at the 39 end of the genome RNA and
proceeds via a sequential start-stop mechanism to pro-
duce the six viral mRNAs. Transcription initiation and
termination on each gene are mediated by conserved
sequences termed gene start and gene stop, which are
found at the beginning and end of each gene, respec-
tively. After the initial transcription phase, the genomic
RNP must be replicated. Like transcription, this RNA1 To whom reprint requests should be addressed at Department of
irology, NC20. Fax: (216) 444-0512. E-mail: banerja@ccf.org.
151synthesis initiates at the 39 end of the genomic RNA [the
leader (Le) promoter]. However, during replication the
nascent RNA is encapsidated and the gene stop and
gene start signals are ignored, so the entire genome
RNA is copied into a positive-sense replication product
called the antigenome. The 39 end of the antigenome
then serves as a replication promoter [trailer comple-
mentary (TrC) promoter] for synthesis of genomic RNA.
The recent development of reverse genetics systems
for the rhabdoviruses and paramyxoviruses has provided
valuable new tools to investigate in greater detail the
roles of the cis-acting RNA elements involved in replica-
tion and transcription. In these systems, a plasmid-de-
rived RNA containing the viral cis-acting replication sig-
nals (a minigenome) can be replicated in cells in which
the viral replication proteins are also expressed. For the
rhabdoviruses and most of the paramyxoviruses [except
respiratory syncytial virus (RSV), which requires one ad-
ditional protein (Collins et al., 1996b)], the N, P, and L
proteins are sufficient to promote viral replication and
transcription. We have created such a minigenome for
HPIV3 and have previously analyzed the cis-acting se-
quences involved in promoting replication and transcrip-
tion (Hoffman and Banerjee, 2000). We were able to
demonstrate that nucleotides 1–12 (from the terminus) of
the leader promoter formed a domain critical for HPIV3
replication. The region from nucleotide 13 to 55 formed a
domain involved in replication but not critically. Finally, a
third domain consisting of G residues at positions 79, 85,
and 91 was critical for replication. Surprisingly, no muta-
tions in these regions caused defects in transcription,
although many severe mutations could not be assayed
for transcription. Mutations in the intergenic sequence
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did disrupt transcription, however.
We wanted to more thoroughly examine the terminal
sequences of HPIV3 genomic and antigenomic RNA and
their roles in transcription and replication, largely be-
cause of two unusual features of the HPIV3 termini that
distinguish it from other paramyxoviruses. Computer-
predicted RNA folding has shown that the HPIV3 termini
have the potential to form stable stem-loop structures
(Fig. 1A). Although no role has been demonstrated for
such stem-loop structures with any paramyxovirus or
rhabdovirus, these structures have been shown to be
involved in the replication of influenza and some posi-
tive-strand RNA viruses (Hsu et al., 1987; Fodor et al.,
1994; Rueckert, 1996; Shaw, 1996). The second unusual
feature of the HPIV3 termini is the extent of terminal
complementarity, 17 bases, which is the most for any
paramyxovirus. For example, with Sendai virus (SeV), a
paramyxovirus related to HPIV3, the terminal comple-
mentarity is 12 bases and, with vesicular stomatitis virus
(VSV), the prototypical rhabdovirus, it is only 8 bases.
Experiments that have extended the terminal comple-
mentarity of VSV have suggested that increased comple-
mentarity results in increased replication (Wertz et al.,
1994). However, other studies with VSV and SeV have
suggested that the increased replication is due to the
strength of the replication promoters more than to the
FIG. 1. (A) HPIV3 genomic termini. The sequence at the HPIV3
genomic termini and possible computer-predicted secondary structure
is shown. Terminal complementarity is shown by bases in outline. (B)
Structure of the HPIV3 minireplicon, pHPIV3MG(2). Transcription from
the plasmid is directed by a T7 RNA polymerase promoter (T7). The
primary transcript is negative sense and contains two nonviral Gs,
followed by sequence encoding the viral trailer (tr), a gene end signal
(GE), part of the L gene 39 NTR, the luciferase gene, part of the N gene
9 NTR, a gene start signal (GS), the viral leader (le), the hepatitis delta
irus ribozyme (Rz), and a T7 RNA polymerase transcription termination
ignal.degree of terminal complementarity (Tapparel and Roux,
1996; Li and Pattnaik, 1997). Thus we decided to look atterminal complementarity differently. Rather than in-
creasing terminal complementarity, we introduced muta-
tions within this region to disrupt the natural terminal
complementarity. Second site mutations were then cre-
ated that restore the base pairing disrupted by the orig-
inal mutation. We also examined the terminal stem-loop
structures in a similar manner. We should note that base
pairing between the termini and formation of the terminal
hairpins are mutually exclusive. However, one of our
hypotheses was that base pairing between the termini
may promote replication, as was seen by Wertz et al.
(1994), whereas formation of the terminal hairpin could
promote transcription. Using the aforementioned ap-
proach, the present results demonstrate that primary
sequence rather than secondary structure plays a major
role in HPIV3 RNA transcription and replication.
RESULTS
Creation and analysis of terminal complementarity
and stem-loop structure mutations
We investigated the role of RNA secondary structure
by first creating leader mutations (Fig. 1A) in an HPIV3
minireplicon (Fig. 1B) that disrupt either terminal comple-
mentarity (le13–16) or both terminal complementarity and
stem-loop structure (le9,10 and le5). In these mutations,
each indicated base was changed to its complementary
base. For example, le5 indicates that leader base 5 was
changed from a U to an A, whereas le13–16 indicates a
change of leader bases 13–16 from UUCU to AAGA. Our
goal with these mutations was not to completely disrupt
secondary structure but rather to perturb it. A good deal
of evidence exists that relatively subtle secondary struc-
ture mutations have a significant impact on RNA–protein
interactions. Binding of TAT to the TAR element of HIV1
and interactions of viral and cellular proteins with the
59-terminal cloverleaf structure of poliovirus are good
examples (Delling et al., 1992; Andino et al., 1990; Ga-
marnik and Andino, 2000). Based on earlier analysis of
the primary sequence in this area of the leader promoter
(the le5 mutation has been described previously but is
included here for continuity), these mutations were pre-
dicted to disrupt replication. To confirm this, these mu-
tations were assayed by transfecting the minireplicon
encoding plasmids along with plasmids encoding the
HPIV3 N, P, and L proteins into HeLa cells infected with
a recombinant vaccinia virus that expresses T7 RNA
polymerase. Expression of the HPIV3 N protein results in
encapsidation of the minireplicon RNA, which then
serves as a template for replication and transcription of
the minigenome RNA by the viral L and P proteins. Cell
extracts were then analyzed for luciferase activity, RNA
transcription, and positive- and negative-sense replica-
tion products.Luciferase expression for all three mutations was sig-
nificantly reduced; the le5 and le13–16 mutations were
153ROLE OF RNA SECONDARY STRUCTURES OF HPIV3about 40% of wild-type levels, whereas that of le9,10 was
only 2% (Fig. 2A). Because the luciferase assay was an
indirect measure of transcription and replication, we an-
alyzed the RNAs synthesized during minigenome repli-
cation. Total RNA was isolated from cells, and plus-
strand RNA synthesis was measured using a primer
extension assay as described in Materials and Methods.
The primer used anneals to the positive-sense luciferase
coding sequence at the initiating AUG codon. This primer
thus anneals to the luciferase-containing transcription
product and the antigenomic replication product. The
extension reaction was performed with Moloney murine
leukemia virus reverse transcriptase for 1 h at 42°C. This
analysis confirmed that luciferase expression correlated
with luciferase expression as the transcription levels of
le5 and le13–16 were 46% and 50%, respectively,
whereas that of le9,10 was 1% (Fig. 2B).
The positive-sense replication product can also be
seen in this same primer extension reaction (Fig. 2B).
However, accurate quantification of the positive-sense
FIG. 2. Analysis of leader stem-loop structure mutations. One hour
after infection with a recombinant vaccinia virus (MVA) that expresses
T7 RNA polymerase, plasmids derived from pHPIV3MG(2) and con-
taining the indicated mutations were transfected into HeLa cells along
with support plasmids encoding the HPIV3 N, P, and L proteins. Lysates
were prepared 28 h posttransfection and assayed by luciferase activity
(A), primer extension of positive-sense RNA products using a total RNA
extract (B), and primer extension analysis of micrococcal nuclease-
treated RNA extracts using primers specific for the positive-sense
replication product (C) or negative-sense replication product (D). The
dideoxy sequencing ladders were made using the same primers as in
the extension reactions and pHPIV3MG(2) as the template. Relevant
regions of the sequences are denoted. In panel B, the figure has been
condensed by the removal of the region between the replication and
transcription extension products. The percent transcription (B) and
positive (C)- and negative (D)-strand replication relative to the wild-type
clone is also shown. These numbers are averages calculated from this
autoradiogram and additional experiments.replication products was somewhat difficult because of
the low intensity of the bands relative to background. Tosolve this problem, we treated cytoplasmic extracts with
micrococcal nuclease. This treatment results in the di-
gestion of nonencapsidated RNAs (T7- and HPIV3-di-
rected transcripts), whereas encapsidated RNAs (repli-
cation products) remain intact. After RNA isolation from
this extract, primer extension was performed as de-
scribed previously for the positive-sense replication
product. The negative strand was analyzed using avian
myoblastosis virus (AMV) reverse transcriptase at 52°C
and a primer that anneals 101 nucleotides from the end
of the replicated negative-strand RNA.
The micrococcal nuclease treatment completely di-
gested the transcription products (data not shown),
whereas the replication products were resistant to mi-
crococcal nuclease digestion (Figs. 2C and 2D). How-
ever, despite this treatment, a background band that
comigrated with the positive-sense replication band [Fig.
2C, wt (2L)] was apparent. We do not know the origin of
this background extension product. This background
was approximately 5% the intensity of that obtained
when the L plasmid was included in the transfection. The
primer extension for the negative-sense replication prod-
uct did not produce any such background [Fig. 2D, wt
(2L)]. Also note that the primer extension revealed a
negative-sense replication product (Fig. 2D) that had lost
the two 59, nonviral G residues, which served to increase
T7-dependent transcription from the minireplicon plas-
mid. Thus the negative-sense replication products we
detect are all generated from HPIV3-directed replication.
This analysis showed that the le9,10 mutation completely
abrogates all replication, whereas the le5 and le13–16
mutations affect primarily synthesis of the positive-sense
replication product. The le5 and le13–16 mutations re-
duce synthesis of these positive-sense replication prod-
uct to 21% and 31% of wild-type, respectively (Fig. 2C).
The negative-strand synthesis was 31% for le5 and 52%
for le13–16. This analysis also demonstrates that these
mutants are not defective in transcription, because tran-
scription is not significantly reduced relative to the
amount of the negative-sense replication product, which
is the template for replication.
Restoration of terminal complementarity and/or stem-
loop structures
Second-site mutations were then made in the le5,
le9,10, and le13–16 mutants, which restore terminal
complementarity or stem-loop structure but not the wild-
type sequence (Fig. 3). Because any increase in replica-
tion should result in increased template for transcription,
and thus transcription and luciferase activity, the second-
site mutants were analyzed using the luciferase assay to
determine whether restoration of RNA structure resulted
in increased luciferase activity.As previously discussed, the le13–16 mutation was
created to examine the role of terminal complementarity.
154 HOFFMAN AND BANERJEEFIG. 3. Analysis of terminal complementarity and stem-loop structure. Mutations were made that disrupted terminal complementarity, stem-loop
structure, or both. Second-site mutations were then made that restore stem-loop structure or terminal complementarity. The locations of all mutations
are shown in the secondary structure depictions. The le9,10/4X and le5/4 denote constructs that contain four mutations: the original and three
additional ones that restore both terminal complementarity and the leader and trailer stem-loop structures. Each mutation was analyzed by luciferase
assay as described in Materials and Methods. Luciferase expression is shown as a percentage relative to the wild-type construct, pHPIV3MG(2).
(A) Compensatory analysis with le13–16. (B) Compensatory analysis with le9,10. (C) Compensatory analysis with le5.
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from 17 nucleotides to 12 nucleotides and results in
approximately 40% luciferase expression (Fig. 2A). The
equivalent mutation in the trailer region resulted in about
70% luciferase activity (Fig. 3A). Combining the two mu-
tations in a single minireplicon restored terminal comple-
mentarity to 17 nucleotides but did not restore activity.
The double mutant (le13–16/tr13–16) was more severe
than either of the single mutants, with luciferase activity
at 20% of wild-type (Fig. 3A).
The le9,10 mutant was also analyzed in this manner.
This mutation, which reduces the leader helix from 9 bp
to 7 bp, results in very low (2% of wild type) luciferase
expression (Fig. 2B). The mutation, which can restore the
helix, le19,20, when assayed singly, had about 70% ac-
tivity (Fig. 3B). Combining the le19,20 change with the
le9,10 mutation (le9,10/le19,20) to restore the helix to 9 bp
did not increase luciferase expression above that ob-
served with the le9,10 mutation. We also looked at ter-
minal complementarity with the le9,10 mutation. The
tr9,10 mutation was severe like the le9,10 mutation, and
when tr9,10 was combined with the le9,10 mutation
(le9,10/tr9,10), no restoration of activity was observed.
Because it was possible that terminal complementarity
and the helical structures were both important, we con-
structed a quadruple mutant (le9,10/4X) with changes at
le9,10, le19,20; tr9,10, and tr20,21 in which both leader
and trailer stem-loop structures and terminal comple-
mentarity are restored. This mutant also did not restore
luciferase activity (Fig. 3B).
The le5 mutation disrupts the helix at an interior posi-
tion and resulted in 43% luciferase activity (Fig. 2A). The
mutation, which restores the helix base pairing (le24),
had approximately 100% activity when assayed singly
(Fig. 3C). However, when le24 was combined with the le5
mutation (le5/le24), luciferase activity was significantly
increased, indicating that the leader stem-loop structure
may play a role in transcription or replication. Analysis of
terminal complementarity with the le5 mutation showed
that the tr5 mutation had little effect on luciferase activity
and the le5/tr5 combination did not result in a significant
increase in luciferase expression. The quadruple mutant
le5/4X resulted in increased luciferase expression, prob-
ably due to the presence of the le24 mutation (Fig. 3C).
This series of studies suggested that the leader stem-
loop structure may have a role in replication, whereas
the terminal complementarity appears not to have a
discernible role in these processes. We investigated
these possibilities further by combining leader and trailer
mutations at positions 2, 4, 6, and 12. Individually, all of
these mutations were severe. We observed that these
double mutants, which restore terminal complementarity,
were unable to restore luciferase activity (Fig. 4A). To
determine the role of the leader stem-loop structure and
the mechanism by which the le24 mutation restores
activity, additional stem-loop compensatory mutationswere made with leader mutations at positions 2, 3, 6, and
8, all of which are severe mutations, reducing luciferase
activity to 1–3% of wild type. As shown in Fig. 4B, the
restoration of base pairing did not result in increased
activity for any of these mutants, unlike the result ob-
served with le5. Another possible mode of action for le24
was as a general enhancing mutation that would in-
crease luciferase activity with mutations other than le5.
To examine this possibility, we combined the le24 muta-
tion with the le2 and le9 mutations and observed signif-
icant increases in luciferase activity (Fig. 5A). Luciferase
expression increased from 2% with the le2 and le9 indi-
vidual mutations to approximately 16% with both le2/le24
and le9/le24. We also combined the le24 mutation with
tr4 and tr10 mutations (Fig. 5A). In this case, luciferase
expression rose from 10% with the tr4 mutation to 42%
with tr4/le24 and from 3% with tr10 to 22% with tr10/le24.
To further confirm this finding and to determine the
mechanism by which the le24 mutation increased lucif-
erase activity, we carried out a primer extension analysis
with these constructs. As shown in Fig. 5C, both positive-
strand replication and transcription are increased when
the le24 mutation was combined with the le5 mutation
(Fig. 5B). However, to our surprise, no increase in the
HPIV3-specific transcript was detected with the le9/le24,
tr4/le24, and tr10/le24 combinations (Fig. 5B). When the
positive- and negative-sense replication products were
examined by primer extension, similar results were seen
(Figs. 5C and 5D). None of the le9/le24, tr4/le24, or
tr10/le24 combinations resulted in increased replication,
whereas an increase was observed with the le5/le24
combination.
DISCUSSION
Previous analysis has shown that bases 1–12 at the
termini of the HPIV3 genome were critical for promoting
replication, whereas bases 13–55 of the leader were of
moderate importance in promoting replication (Hoffman
and Banerjee, 2000). We wanted to know whether any
importance of these regions may be due to RNA second-
ary structure formation. HPIV3 has the potential to form a
9-bp stem-loop structure within the leader region, an 11
bp stem-loop structure within the trailer region, and a
17-bp interaction between the termini.
In this analysis, we were unable to demonstrate any
evidence of a role for RNA secondary structure in HPIV3
transcription or replication. Disruption of the proposed
leader stem-loop structure did disrupt replication; how-
ever, restoration of the structure did not restore activity,
indicating that the mutation of the primary sequence was
the main cause of the reduced activity. Similarly, disrup-
tion of the natural terminal complementarity did interfere
with viral replication, but restoration of terminal comple-
mentarity did not increase replication. We conclude that
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element controlling RNA transcription and replication.
The le24 mutation proved interesting in that it appears
to have different effects, depending on the mutant back-
ground in which it is placed. In combination with the le24
mutation, it clearly enhances replication, which results in
increased transcription and luciferase activity. However,
in combination with le2, le9, tr4, and tr10 mutations, it
also appears to enhance luciferase expression but not
RNA replication or transcription. We repeated the lucif-
erase and primer extension assays many times and
always obtained the same result. We have also per-
formed both luciferase assays and primer extension as-
says using the same transfected cells. In one case, we
FIG. 4. Additional compensatory analysis of terminal complementar
mentarity. Mutations at leader positions 2, 4, 6, and 12 that disrupt term
trailer. By combining mutations at a given position in the leader and tra
Compensatory analysis of the leader stem-loop structure. Additional m
combined with mutations that restore helix base pairing (positions 27,
previously. Luciferase expression is shown as a percentage relative toobserved luciferase activity of the tr4/le24 mutation at
50% of wild-type levels, whereas primer extension of
i
tRNA from the same cells revealed only 7% the transcrip-
tion of wild-type levels. Because the primer used for
primer extension anneals within the luciferase se-
quence, an increase in any RNA product that could be
translated to produce luciferase should be visible. This
has not been observed in readable portions of the auto-
radiographs. However, it is possible that there is an
increase in a nonspecific transcript that has a 59-termi-
us close to the luciferase AUG. Such an RNA would be
ifficult to detect with the primer extension assay be-
ause there are considerable short, nonspecific back-
round extension products (of 1–22 nucleotides) in this
rea of the autoradiographs (data not shown). Another
ossible explanation is that the le24 mutation does not
stem-loop structure. (A) Compensatory analysis of terminal comple-
plementarity were combined with the corresponding mutations in the
minal complementarity was restored but not the original sequence. (B)
s that disrupt the leader helix structure at positions 2, 3, 6, and 8 were
, and 21, respectively). All mutations were then assayed as described
3MG(2).ity and
inal com
iler, ter
utationncrease transcription but enhances translation of cer-
ain background RNA products. Thus through the use of
157ROLE OF RNA SECONDARY STRUCTURES OF HPIV3the primer extension assay, we were able to show that
the le24 mutation does increase transcription/replication
when combined with the le5 mutation but not with the
le2, le9, tr4, or tr10 mutations. We are working to detect
FIG. 5. Analysis of the le24 mutation. (A) The le24 mutation increases
luciferase activity. The le24 mutation was combined with the le2, le5,
le9, tr4, and tr10 mutations and assayed for luciferase activity. The
le5/le24 double mutant was shown previously in Fig. 3C. Luciferase
expression is shown as a percentage relative to pHPIV3MG(2). (C)
Primer extension analysis of positive-sense RNAs with the le24 muta-
tion. Primer extension was performed using total cellular RNA and the
positive-sense specific primer as described in Materials and Methods.
The figure has been condensed by the removal of the region between
the replication and transcription extension products. (C and D) Primer
extension analysis of micrococcal nuclease-treated RNA extracts using
primers specific for the positive-sense replication product (C) or neg-
ative-sense replication product (D).the source of the mRNA that is translated to produce
luciferase. We also want to be clear that we have onlyseen excess luciferase activity and have never seen
transcription in the absence of luciferase expression.
Therefore, we believe that the assays that test for in-
creased luciferase activity with the double mutants that
restore potential base pairing are valid. With these mu-
tants, any increase in transcription would result in in-
creased luciferase activity. Still, the best measure of
transcription is to examine RNA expression directly and
not via reporter expression.
The fact that the addition of the le24 mutation to a
minigenome containing the le5 mutation does act to
enhance replication confirms that this region of leader
does have a role in replication. Our previous analysis of
the 13–55 region of the replication promoter showed that
mutations in this region had no or moderate effects on
replication, with point mutations resulting in 40–100%
activity (Hoffman and Banerjee, 2000). Perhaps the le24
mutation enhances replication by increasing the binding
of proteins that assist in placing the replicase on the
more critical 1–12 domain.
To further investigate and clarify the mechanism by
which the le24 mutation works, we will insert the le5 and
le5/le24 mutations into the HPIV3 infectious clone (Hoff-
man and Banerjee, 1997). Preliminary evidence has
shown that the le5 mutation results in a small plaque
phenotype (data not shown). By combining the le5 and
le24 mutations, we can then determine whether the le24
mutation works in the viral context to increase replication
and plaque size.
MATERIALS AND METHODS
Plasmid construction
Construction of the negative-sense minireplicon,
pHPIV3MG(2), was described previously. Mutations in
pHPIV3MG(2) were made by PCR-directed mutagene-
sis. Mutations in the leader region were made using
primers that encoded a natural SwaI site within the
leader sequence and the desired mutations. The second
PCR primer was pOCUS-UP, which primes within the
vector. The PCR products were digested with SwaI and
BstXI and inserted into the same sites of pHPIV3MG(2).
Trailer region mutations were made using one primer
that encoded an HindIII site and the desired mutation
and another that primes at base 1291 of firefly luciferase.
The PCR products derived thereby were digested with
EcoRV and HindIII and inserted into the same sites of
pHPIV3MG(2).
Luciferase assay
HeLa cell monolayers were grown on 12-well plates to
90% confluency and infected with recombinant vaccinia
virus MVA (Wyatt et al., 1995), which expresses T7 RNA
polymerase, at a multiplicity of infection of 3. After 1 h at
37°C, the minireplicon and support plasmids were trans-
a
u
r
t
4
r
o
g
g
u
r
6
r
p
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ries) according to the manufacturer’s instructions. The
plasmid amounts that we used were 200 ng of pPIV3-
MG(2), 640 ng of pPIV3-N, 1000 ng of pPIV3-P, and 100
ng of pPIV3-L. After 4 h, the transfection medium was
removed and replaced with 1 ml of Dulbecco’s modified
Eagle’s medium–5% fetal calf serum. At 28 h posttrans-
fection, the monolayers were lysed in 150 ml of lysis
buffer from which 1.5 ml lysate (equivalent to 2.3 3 103
cells) was then used to determine luciferase activity in a
Dynatech ML2250 luminometer according to the manu-
facturer’s specifications (Luciferase Assay Kit; Boehr-
inger-Mannheim Biochemicals, Indianapolis, IN).
RNA analysis
HeLa cells were transfected as described above ex-
cept that 6-well plates were used and all material
amounts were increased proportionately. For the extrac-
tion of total RNA, the cells were lysed and RNA was
purified with RNA STAT-60 (Tel Test B, Friendswood, TX)
according to the manufacturer’s specifications. For iso-
lation of replication-specific RNA, the cells were lysed
and the nonencapsidated RNA was digested with micro-
coccal nuclease as described by Durbin et al. (1997) and
then extracted with RNA STAT-60.
Primer extension analysis was performed using a neg-
ative-sense, g-32P-ATP end-labeled oligomer that primes
t nucleotide 2 of the luciferase gene. This primer was
sed with 50% of the total RNA extract in a standard RT
eaction with Moloney murine leukemia virus reverse
ranscriptase (Boehringer-Mannheim Biochemicals) at
2°C. Primer extension analysis of the negative-sense
eplication product was performed using an end-labeled
ligomer that primes at nucleotide 1649 of the luciferase
ene, which is 101 nucleotides from the 59 end of the
enomic RNA. This primer extension was performed
sing AMV reverse transcriptase at 52°C in a standard
eaction. The extension products were separated on a
% acrylamide–7 M urea gel and analyzed by autoradiog-
aphy and quantification on a Molecular Dynamics Phos-
horImager (Sunnyvale, CA).
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